Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: A study using codeine in methadone- and buprenorphine-maintained subjects

British Journal of Clinical Pharmacology

Volumn 73, Issue 5, 2012, Pages 786-794

  Gelston, Eloise A ^a   Coller, Janet K ^a   Lopatko, Olga V ^a   James, Heather M ^b   Schmidt, Helmut ^c   White, Jason M ^d,e   Somogyi, Andrew A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SA PATHOLOGY   (Australia)

^c GOETHE UNIVERSITY   (Germany)

^d Drug & Alcohol Services South Australia   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Buprenorphine; Codeine metabolism; CYP2D6 inhibition; Glucuronidation inhibition; Methadone

Indexed keywords

BUPRENORPHINE; CODEINE; CODEINE 6 GLUCURONIDE; CODEINE PHOSPHATE; CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; N DEMETHYLASE; NORCODEINE; O DEMETHYLASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; GLUCURONIDATION; HUMAN; IN VIVO STUDY; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CODEINE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; METHADONE; MIDDLE AGED; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84859417556     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04145.x     Document Type: Article

References (40)

1. O'Brien S. Treatment Options for Heroin and Other Opioid Dependence - A Guide for Users. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2004.
2. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289: 2370-8.
3. Mikus G, Somogyi AA, Bochner F, Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol 1991; 41: 757-62.
4. Rossi S, ed. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2011.
5. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988; 2: 914-5.
6. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991; 31: 381-90.
7. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 db1/bufI). Biochem Biophys Res Commun 1988; 152: 411-6.
8. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH. Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-95.
9. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009; 65: 121-39.
10. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165-71.
11. Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006; 79: 35-48.
12. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-44.
13. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45-52.
14. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345-472.
15. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11: (2 Suppl.): S133-53.
16. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003; 31: 1125-33.
17. Miners JO, Mackenzie PI, Knights KM. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 2010; 42: 196-208.
18. Morrish GA, Foster DJ, Somogyi AA. Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. Br J Clin Pharmacol 2006; 61: 326-35.
19. Caraco Y, Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab dispos 1996; 24: 761-4.
20. Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 1992; 13: 445-60.
21. Yue QY, Hasselstrom J, Svensson JO, Sawe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991; 31: 635-42.
22. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37.
23. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
24. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003; 33 (Suppl. 2): 17-22.
25. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35: 30-4.
26. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994; 38: 243-8.
27. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47: 403-12.
28. Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 2011; 108: 55-62.
29. Somogyi AA, Coller JK. Analgesic and adjuvant drugs. In: Metabolism of Drugs and Other Xenobiotics. Berlin: Wiley-VCH, 2011 (in press).
30. Iribarne C, Picart D, Dréano Y, Bail J-P, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60: 1953-64.
31. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38: 40-5.
32. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 2004; 42: 719-23.
33. Somogyi AA, Larsen M, Abadi RM, Jittiwutikarn J, Ali R, White JM. Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 2008; 66: 640-7.
34. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J-THA, Lötsch J, Roots I, Brockmöller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7: 257-65.
35. Foster DJ, Morton E, Murtder T, Somogyi A. Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject. Ther Drug Monit 2006; 28: 559-67.
36. Newcombe RG. Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 1: general issues and tail-area-based methods. Stat Med 2006; 25: 543-57.
37. Newcombe RG. Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 2: asymptotic methods and evaluation. Stat Med 2006; 25: 559-73.
38. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22: 541-50.
39. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica 1998; 28: 1255-73.
40. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther 2010; 334: 609-18.